Clinical trial

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

NCT03911193

Study summary

ClinicalTrials.gov

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Cabozantinib Normalized identity: cabozantinib View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-09-21

PhasePHASE2

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

CabozantinibDRUG · verified · RxNorm: cabozantinib

Sponsors & collaborators

Fondazione Ricerca Traslazionalelead sponsor

Mapped research locations

VeronaItaly1 MilanMI, Italy1 RomaRM, Italy1 RavennaItaly1 PisaPI, Italy1 FlorenceFI, Italy1 BariBA, Italy1 PadovaPD, Italy1 OrbassanoTorino, Italy1 PalermoPA, Italy1 ModenaMO, Italy1 ParmaPR, Italy1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03911193 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.